Early Diagnosis and Therapeutic Strategies for Hepatocellular Carcinoma: from Bench to Bedside

Ming‐Cheng Guan,Mingda Wang,Siyu Liu,Wei Ouyang,Lei Liang,Timothy M. Pawlik,Qiuran Xu,Dongsheng Huang,Feng Shen,Hong Zhu,Tian Yang

DOI: https://doi.org/10.4251/wjgo.v13.i4.197

2021-01-01

World Journal of Gastrointestinal Oncology

Abstract:Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide. The prognosis of patients with HCC remains poor largely due to the late diagnosis and lack of effective treatments. Despite being widely used, alpha-fetoprotein serology and ultrasonography have limited diagnostic performance for early-stage HCC. The emergence of omics strategies has contributed to significant advances in the development of non-invasive biomarkers for the early diagnosis of HCC including proteins, metabolites, circulating tumor deoxyribonucleic acid, and circulating non-coding ribonucleic acid. Early diagnosis is beneficial to patients as it increases the proportion who can be treated with curative treatment, thus prolonging survival outcomes. Currently, multiple clinical trials involving locoregional, systemic therapies, and combinations of these modalities are changing therapeutic strategies for different stage HCC. Success in several preclinical trials that involve immunotherapeutic innovations has created the potential to complement and enforce other treatment strategies in the future. This review summarizes the most recent advances in non-invasive early molecular detection, current therapy strategies, and potential immunotherapeutic innovations of HCC.